| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/31/2003 | WO2003030872A3 Compositions having a combination of particles for immediate release and for controlled release |
| 07/31/2003 | WO2003026615A3 Modified release dosage forms |
| 07/31/2003 | WO2003020242A9 Sustained release preparations |
| 07/31/2003 | WO2003015825A3 Conjugate |
| 07/31/2003 | WO2003007995A3 Pharmaceutical preparations containing ion exchange resins charged with fluoroquinolone |
| 07/31/2003 | WO2003007867A3 A salt/ion pair medicinal aerosol formulation |
| 07/31/2003 | WO2002098453A3 Orally administering parathyroid hormone and calcitonin |
| 07/31/2003 | WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 07/31/2003 | WO2002043772A3 Water-soluble polymer conjugates of triazine derivatives |
| 07/31/2003 | WO2002036169A3 Methods and compositions for enhanced delivery of bioactive molecules |
| 07/31/2003 | WO2001097855A3 Targeted combination immunotherapy of cancer and infectious diseases |
| 07/31/2003 | WO2001095942A3 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| 07/31/2003 | WO2001080902A8 A particulate complex for administering nucleic acid into a cell |
| 07/31/2003 | WO2001062298A9 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 07/31/2003 | US20030144635 Method to use transdermal administration of androgens to the adnexa of the eye |
| 07/31/2003 | US20030144498 Binding antibody to tyrosine kinase; neovascularization; antitumor agent |
| 07/31/2003 | US20030144474 T cell receptor and a biologically active polypeptide with different recognition biding sites connected by a peptide linker; designed to redirect the immune system against various diseases |
| 07/31/2003 | US20030144458 Novel amphiphilic polymeric materials |
| 07/31/2003 | US20030144356 Formulation |
| 07/31/2003 | US20030144355 Stabilisation of pigments and polyunsaturated oils and oil concentrates |
| 07/31/2003 | US20030144306 A liquid oral composition comprising a proton pump inhibitor, e,g, omeprazole, lansoprazole,and a buffer; can also contain a parietal cell activator; acid resistance; side effect reduction; kits; drug delivery; Zollinger-Ellison syndrome |
| 07/31/2003 | US20030144247 Obtained by reacting polyalkylene glycol or a reactive derivative, a phospholipid and a drug with each other to form covalent bonds to form a delivery substance |
| 07/31/2003 | US20030144244 Stable compositions of S-adenosyl-l-methionine with dextran |
| 07/31/2003 | US20030144230 Covalent coupled of nucleic acids, peptides or proteins to active material for enhancing transfection efficiency; potentiation |
| 07/31/2003 | US20030144222 Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| 07/31/2003 | US20030144207 Hydrophilic conjugate having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer |
| 07/31/2003 | US20030144199 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 07/31/2003 | US20030144198 Increasing gastrointestinal absorption |
| 07/31/2003 | US20030144197 Autologous growth factor cocktail composition, method of production and use |
| 07/31/2003 | US20030144189 Endothelial growth factor-follicle stimulating hormone compounds having increased serum half-lives relative to native hormones; for increasing fertility, egg production and spermatogenesis, and increasing vascularization in tissue |
| 07/31/2003 | US20030144181 Insoluble compositions for controlling blood glucose |
| 07/31/2003 | US20030143739 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143684 Combining a compound to be tested, a host cell expressing a recombinant protein containing a mammalian C-C chemokine receptor 3 and a ligand for binding of ligand to such receptor, detecting the formation of a receptor-ligand complex |
| 07/31/2003 | US20030143655 For competitive immunoassays for detection of lysergic acid (LAD) metabolite; drug screening; forensics |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143596 Branched water soluble polymers containing atleast two arms, such as polyoxyethylene glycol, linked to a central aliphatic hydrocarbon core molecule through heteroatom linkage and one functional group for reacting biological active agent |
| 07/31/2003 | US20030143312 Baking adjuvant |
| 07/31/2003 | US20030143281 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143279 Method for preparing microparticles having a selected polymer molecular weight |
| 07/31/2003 | US20030143277 Drug delivery system |
| 07/31/2003 | US20030143269 Tamper-resistant oral opioid agonist formulations |
| 07/31/2003 | US20030143268 Three-dimensional printing process; uniaxially compressing the dosage form |
| 07/31/2003 | US20030143267 Sugar-modified liposome and products comprising the liposome |
| 07/31/2003 | US20030143265 Administering riboflavin or derivatives |
| 07/31/2003 | US20030143262 Hygiene tissue |
| 07/31/2003 | US20030143257 For controlled release of the drug |
| 07/31/2003 | US20030143250 Pharmaceutical compositions comprising cyclosporins |
| 07/31/2003 | US20030143248 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 07/31/2003 | US20030143234 For therapy of microbial organism infection |
| 07/31/2003 | US20030143233 For use in diagnosis, therapy |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143217 For therapy of smooth muscle cell hyperplasia; cancer therapy |
| 07/31/2003 | US20030143195 Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery |
| 07/31/2003 | US20030143189 Therapy for topical diseases |
| 07/31/2003 | US20030143186 For use in personal care formulations such as body washes, shampoos, and skin creams |
| 07/31/2003 | US20030143185 Polymer conjugates of protein kinase C inhibitors |
| 07/31/2003 | US20030143184 Shelf life of longer than three years in a sterilized container, stability of longer than three days in infusion fluid, has minimal side effects and shows improved bioavailability |
| 07/31/2003 | US20030143165 Regularly applying a topical formulation to the skin of patient, formulation containing a pharmaceutically effective amount of a non- steroidal anti-inflammatory drug |
| 07/31/2003 | US20030143163 For therapy of respiratory disorders; aerosol formulations of use for the administration of medicaments by inhalation |
| 07/31/2003 | US20030143161 Medicine, carrier for medicine, method of producing medicine, and method of tumor treatment |
| 07/31/2003 | US20030140921 Methods and systems for operating an aerosol generator |
| 07/31/2003 | US20030140920 Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma |
| 07/31/2003 | DE29824938U1 Pharmaceutical preparation comprising clodronate |
| 07/31/2003 | CA2840490A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2753899A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2511257A1 Stimulation of bone growth and cartilage formation with thrombin peptide derivatives |
| 07/31/2003 | CA2511223A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | CA2474344A1 Expansion of renewable stem cell populations |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2473927A1 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | CA2473884A1 Method of treatment of a patient requiring analgesia |
| 07/31/2003 | CA2473841A1 Film-forming compositions and methods |
| 07/31/2003 | CA2473748A1 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | CA2473746A1 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/31/2003 | CA2473717A1 Dna dosage forms |
| 07/31/2003 | CA2473679A1 Dna dosage forms |
| 07/31/2003 | CA2473498A1 Water-soluble derivatives of lipophilic drugs |
| 07/31/2003 | CA2473490A1 Peptide-carrying bodies for immune response |
| 07/31/2003 | CA2473395A1 Phospholipid bodies and use thereof in medical treatment |
| 07/31/2003 | CA2473283A1 Process for preparing aqueous-alcoholic solution and products based thereon |
| 07/31/2003 | CA2473059A1 Apparatus and process for preparing crystalline particles |
| 07/31/2003 | CA2473040A1 A weight management system for obese animals |
| 07/31/2003 | CA2472588A1 Oral administration of interferon-tau |
| 07/31/2003 | CA2472564A1 Aqueous antiseptic composition comprising an antimicrobial agent, a high concentration of a hydroxycarboxylic acid buffer, and a cationic film-forming polymer |
| 07/31/2003 | CA2471740A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | CA2469721A1 Stabilized formulations of adenovirus |
| 07/31/2003 | CA2441796A1 Solid orally-dispersible pharmaceutical formulation |
| 07/30/2003 | EP1331013A2 Improvements in or relating to contrast agents |
| 07/30/2003 | EP1331002A2 Oil-free pharmaceutical compositions containing cyclosporin A |
| 07/30/2003 | EP1331001A1 Novel dispersible and soluble galenic paracetamol formulation, method for its preparation and its applications |
| 07/30/2003 | EP1330520A2 Therapeutic oligonucleotides of reduced toxicity |
| 07/30/2003 | EP1330477A2 Rheology modifying copolymer composition |
| 07/30/2003 | EP1330447A2 Peptides as met-ap2 inhibitors |
| 07/30/2003 | EP1330441A2 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections |
| 07/30/2003 | EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 07/30/2003 | EP1330268A1 Targeted therapeutic agents |
| 07/30/2003 | EP1330266A1 Method for making very fine particles consisting of a principle inserted in a host molecule |
| 07/30/2003 | EP1330265A1 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 07/30/2003 | EP1330260A1 Use of il-1 inhibitors and tnf antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia |